Ironwood Pharmaceuticals Inc header image

Ironwood Pharmaceuticals Inc

IRWD

Equity

ISIN null / Valor 10773079

NASDAQ (2026-11-05)
USD 4.03+6.90%

Ironwood Pharmaceuticals Inc
UMushroom community rating:

star star star star star
3.00 2 votes No rating yet
NegativeNeutralPositive

About company

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal disorders. The company is best known for discovering and developing linaclotide, marketed as Linzess for the treatment of irritable bowel syndrome with constipation (IBS‑C) and chronic idiopathic constipation (CIC), which serves as a principal source of revenue through product sales, royalties and collaboration agreements. Ironwood maintains a research and development pipeline of earlier‑stage candidates aimed at GI motility and related pain mechanisms, funds its operations through a combination of product-derived revenues and strategic partnerships/license arrangements, and is headquartered in the Boston area.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

95.6%1Y
-57.6%3Y
%5Y

Performance

87.7%1Y
95.3%3Y
87.7%5Y

Volatility

Market cap

666 M

Market cap (USD)

Daily traded volume (Shares)

4,989,224

Daily traded volume (Shares)

1 day high/low

4.495 / 4.34

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

3.00

2 votes
Performance:
starstarstarstarstar
2.50
Innovation:
starstarstarstarstar
3.50
Society:
starstarstarstarstar
2.50
Nature:
starstarstarstarstar
2.00
Kian Mazloum
UK, 03 Nov 2025
star star star star star
Great potential and recent record
David Cann
UK, 03 Nov 2025
star star star star star
Bad stock

EQUITIES OF THE SAME SECTOR

Sanofi SA
Sanofi SA Sanofi SA Valor: 699381
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.97%EUR 82.44
Galapagos NV
Galapagos NV Galapagos NV Valor: 2130343
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.48%EUR 30.20
Orion Oyj
Orion Oyj Orion Oyj Valor: 2553360
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.60%EUR 101.00
Siemens Healthineers AG
Siemens Healthineers AG Siemens Healthineers AG Valor: 40652181
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.33%EUR 45.00
Beiersdorf AG
Beiersdorf AG Beiersdorf AG Valor: 324660
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.09%EUR 85.86
Merck KGaA
Merck KGaA Merck KGaA Valor: 412799
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.07%EUR 150.35
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA Fresenius SE & Co. KGaA Valor: 332902
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.95%EUR 51.87
Carl Zeiss Meditec AG
Carl Zeiss Meditec AG Carl Zeiss Meditec AG Valor: 1055489
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.06%EUR 35.80
Evotec SE
Evotec SE Evotec SE Valor: 505433
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
7.14%EUR 3.09
Vimian Group AB
Vimian Group AB Vimian Group AB Valor: 111662981
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.48%SEK 42.30